Literature DB >> 29601923

Evaluation and Management of Testosterone Deficiency: AUA Guideline.

John P Mulhall1, Landon W Trost1, Robert E Brannigan1, Emily G Kurtz1, J Bruce Redmon1, Kelly A Chiles1, Deborah J Lightner1, Martin M Miner1, M Hassan Murad1, Christian J Nelson1, Elizabeth A Platz1, Lakshmi V Ramanathan1, Ronald W Lewis1.   

Abstract

PURPOSE: There has been a marked increase in testosterone prescriptions in the past decade resulting in a growing need to give practicing clinicians proper guidance on the evaluation and management of the testosterone deficient patient.
MATERIALS AND METHODS: A systematic review utilized research from the Mayo Clinic Evidence Based Practice Center and additional supplementation by the authors. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions (table 1 in supplementary unabridged guideline, http://jurology.com/).
RESULTS: This guideline was developed by a multi-disciplinary panel to inform clinicians on the proper assessment of patients with testosterone deficiency and the safe and effective management of men on testosterone therapy. Additional statements were developed to guide the clinician on the appropriate care of patients who are at risk for or have cardiovascular disease or prostate cancer as well as patients who are interested in preserving fertility.
CONCLUSIONS: The care of testosterone deficient patients should focus on accurate assessment of total testosterone levels, symptoms, and signs as well as proper on-treatment monitoring to ensure therapeutic testosterone levels are reached and symptoms are ameliorated. Future longitudinal observational studies and clinical trials of significant duration in this space will improve diagnostic techniques and treatment of men with testosterone deficiency as well as provide more data on the adverse events that may be associated with testosterone therapy.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  androgens; hypogonadism; men’s health; testosterone

Mesh:

Substances:

Year:  2018        PMID: 29601923     DOI: 10.1016/j.juro.2018.03.115

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  90 in total

1.  Azoospermia With Testosterone Therapy Despite Concomitant Intramuscular Human Chorionic Gonadotropin: NYU Case of the Month, July 2018.

Authors:  Bobby Najari
Journal:  Rev Urol       Date:  2018

2.  Fertility Related Quality of Life, Gonadal Function and Erectile Dysfunction in Male Partners of Couples with Unexplained Infertility.

Authors:  R Matthew Coward; Christy Stetter; Allen Kunselman; J C Trussell; Mark C Lindgren; Ruben R Alvero; Peter Casson; Gregory M Christman; Christos Coutifaris; Michael P Diamond; Karl R Hansen; Stephen A Krawetz; Richard S Legro; Randal D Robinson; James F Smith; Anne Z Steiner; Robert A Wild; Heping Zhang; Nanette Santoro
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

3.  Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men.

Authors:  Thiago Gagliano-Jucá; Zhuoying Li; Karol M Pencina; Yusnie M Beleva; Olga D Carlson; Josephine M Egan; Shehzad Basaria
Journal:  Endocrine       Date:  2018-09-06       Impact factor: 3.633

Review 4.  Paediatric and adult-onset male hypogonadism.

Authors:  Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi
Journal:  Nat Rev Dis Primers       Date:  2019-05-30       Impact factor: 52.329

5.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

Review 6.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

Review 7.  Pituitary Dysfunction Among Men Presenting with Hypogonadism.

Authors:  Shiri Levy; Mingxue Arguello; Mohamed Macki; Sudhaker D Rao
Journal:  Curr Urol Rep       Date:  2019-11-16       Impact factor: 3.092

8.  The association between plant-based content in diet and testosterone levels in US adults.

Authors:  Manish Kuchakulla; Sirpi Nackeeran; Ruben Blachman-Braun; Ranjith Ramasamy
Journal:  World J Urol       Date:  2020-05-28       Impact factor: 4.226

9.  Testosterone therapy: Prescribing and monitoring patterns of practice in British Columbia.

Authors:  Jennifer A Locke; Ryan Flannigan; Oliver P Günther; Sean Skeldon; S Larry Goldenberg
Journal:  Can Urol Assoc J       Date:  2021-02       Impact factor: 1.862

10.  Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.

Authors:  Reith R Sarkar; Sunil H Patel; J Kellogg Parsons; Rishi Deka; Abhishek Kumar; John P Einck; Arno J Mundt; A Karim Kader; Christopher J Kane; Paul Riviere; Rana McKay; James D Murphy; Brent S Rose
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-06-08       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.